Raymond James Financial Inc. Makes New $3.86 Million Investment in DaVita Inc. (NYSE:DVA)

Raymond James Financial Inc. purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 25,836 shares of the company’s stock, valued at approximately $3,864,000.

A number of other large investors also recently made changes to their positions in DVA. Franklin Resources Inc. grew its stake in DaVita by 134.6% in the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock valued at $8,885,000 after purchasing an additional 31,502 shares during the period. FMR LLC increased its stake in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Atom Investors LP purchased a new position in DaVita in the 3rd quarter worth approximately $4,094,000. Assenagon Asset Management S.A. lifted its stake in DaVita by 201.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock worth $11,159,000 after purchasing an additional 49,885 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new position in DaVita during the third quarter valued at approximately $726,000. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

DVA has been the subject of several recent research reports. Barclays boosted their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. StockNews.com lowered shares of DaVita from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, DaVita currently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Trading Up 0.3 %

Shares of DaVita stock opened at $151.30 on Thursday. The stock has a market capitalization of $12.10 billion, a PE ratio of 14.09, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company’s fifty day simple moving average is $157.96 and its 200-day simple moving average is $157.53. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.